India MCA Insolvency Liquidation Filings — March 21, 2026

CIRP initiated via NCLT order Oct 30, 2025 (CP(IB)/71/KB/2025), IRP Adv. Najeeb T P appointed, signaling default admission

RP appointment confirmed Jan 27, 2026 (IA(IB.C)/90(KB)2026), extending insolvency control over management

5th COC meeting held March 21, 2026 (4-5:48 PM), focused on CIRP costs to date and additional support needs without resolutions

Resolution plans accepted post-deadline up to March 17, 2026 midnight, indicating weak bidder interest or process delays

Discussions on interim finance from financial creditors highlight acute liquidity crunch in advanced CIRP stage

NCLT Mumbai admits CIRP March 17, 2026 (CP(IB)/579/MB/2025) on ₹7.47 Cr default, debtor withdrew objections and admitted claim in full

Operational debt default dated Nov 7, 2023 (₹6.19 Cr principal from ₹18.36 Cr invoices after ₹12.17 Cr payments + ₹1.28 Cr interest)

Moratorium declared under Section 14 IBC, prohibiting asset transfers, suits, and recoveries as of March 17, 2026

2/3 filings on same company show repeated disclosures of stalled CIRP progress over 5 months

No insider buying, capital allocation, or positive forward guidance; 100% negative sentiment vs prior stable operations

Prolonged timelines (Radhagobind 5th COC after ~5 months; Remedium admission 2.5 years post-default) vs typical 180/330-day IBC clocks

Zero financial metrics/operational trends disclosed, masking deeper balance sheet deterioration

5th COC on March 21, 2026 without plan approvals risks missing 180-day resolution deadline (~April 2026)

Ongoing CIRP costs and interim finance needs signal escalating cash burn and creditor fatigue

2.5-year gap from Nov 2023 default to March 2026 admission indicates prior disputes, potential larger hidden debts

Immediate operational halt under Section 14, no asset sales/recoveries, threatens going-concern viability

No quantified resolutions post-March 17 plans; prolonged CIRP raises Section 33 liquidation probability

Proposed IRP Mr. Rajesh Jhunjhunwala pending confirmation, delays COC formation and plan invites

3/3 filings in 1 day (March 21 period) suggest rising small-cap defaults amid economic stress

CIRP creditor control (operational/financial) typically dilutes equity to zero without strong plans

₹7.47 Cr admitted debt (healthcare ops creditor) may balloon with other claims post-COC

Scrip codes BSE 030070/CSE 539673 likely face suspension post-CIRP disclosures

Late plans accepted to March 17, 2026; undervalued trading assets (CIN L51909WB) for acquirers at distress pricing

₹7.47 Cr operational debt admitted; financial creditors can inject interim finance for control premium

COC seeking support services/finance; yield >20% potential for bridge lenders pre-resolution

Fresh CIRP (March 17 start), healthcare assets post-₹12.17 Cr payments suggest recoverable value vs debt

Listed small-caps (BSE/CSE scrips) primed for 50-90% drawdowns on IBC news, low float amplifies moves

March 21 meeting outcomes may reveal plan shortlist; early position for favorable resolution vote

Watch first COC ~30 days post-admission; strategic assignment of voting rights to top creditor

If no plans, liquidation auctions offer asset grabs at 10-30% book value in trading/healthcare

Authenticated default via NeSL Form D boosts creditor claims enforceability for recoveries

Physical/VC venue access for bidders to influence 5th+ meetings on plan evaluation

Radhagobind at 5th COC ~5 months post-IRP vs IBC 180-day norm; Remedium 2.5 years default-to-admission, delaying resolutions [Implications: Higher liquidation odds, equity erosion]

Remedium case won by Boston Ivy (₹7.47 Cr claim admitted post-objections withdrawn), bypassing financial creditor priority [Implications: Supplier risks amplified in supply-chain distress]

Radhagobind COC flags interim finance needs/CIRP costs; no capex/dividends possible under moratorium [Implications: Reinforces cash preservation, short-term financing alpha]

Penny scrips (BSE 030070) repeatedly file CIRP updates, 2/3 on same firm; no insider support [Implications: Suspension/delisting waves in trading/healthcare]

3/3 filings at 10/10 materiality, zero positive metrics/forward guidance [Implications: Sector sell-off trigger, portfolio de-risking needed]

Late extensions to March 17 midnight, additional eval support needed; weak bidder pipelines [Implications: Monitor for haircuts >70% on claims]

Outcomes from March 21, 2026 5th meeting on plan shortlisting/CIRP costs; anticipate within 30 days [Watch by April 20, 2026]

Evaluation of plans received up to March 17 midnight; approval/rejection timeline post-COC [Watch by May 2026]

NCLT approval for proposed IRP Mr. Rajesh Jhunjhunwala; impacts COC formation speed [Watch by April 2026]

Formation ~30 days post March 17 admission; claim admissions and plan invite process [Watch by April 20, 2026]

180 days from March 17 (~Sep 13, 2026); extension risks liquidation [Watch quarterly]

Financial creditor infusions discussed March 21; terms and approvals [Watch by April 2026]

Further orders on Kolkata/Mumbai benches for both CIRPs; potential plan approvals or liquidations [Ongoing from March 21, 2026]

Post-moratorium creditor submissions beyond ₹7.47 Cr; debt pile-up via public notice [Watch by May 2026]